Intec Closes Merger with Decoy Biosystems
USA - English
Changes Corporate Name to Indaptus Therapeutics to Reflect Clinical Focus
News provided by
Share this article
Share this article
NEW YORK, Aug. 3, 2021 /PRNewswire/ Indaptus Therapeutics, Inc. (Nasdaq: INDP) ( Indaptus or the Company, and formerly, Intec Parent, Inc.) today announced the closing of its previously announced merger with Decoy Biosystems, Inc. ( Decoy ) and the completion of a $30 million private placement in accordance with the merger agreement. In addition, the Company announced a corporate name change to Indaptus Therapeutics, as it better reflects the Company s therapeutic focus.
Indaptus is expected to begin trading on the Nasdaq Capital Market at the open of trading on August 4, 2021, under the ticker symbol INDP and a new CUSIP number (45339J 105). The previous ticker symbol was NTEC (Nasdaq: NTEC). The Company will have a new website address: www.indaptusrx.com.
Intec Pharma and Decoy Biosystems Announce Merger Agreement
USA - English
Investigational New Drug Application Filing Expected in 2H 2021
News provided by
Share this article
Share this article
JERUSALEM, March 15, 2021 /PRNewswire/ Intec Pharma Ltd. (NASDAQ: NTEC) ( Intec or the Company ) announced today that it has entered into a definitive agreement for a business combination with Decoy Biosystems, Inc., a privately-held, preclinical-stage biotechnology company developing novel, multi-targeted products that safely prime both innate and adaptive anti-tumor and anti-viral immune responses.
The combined company will advance its immunotherapy platform to battle a variety of tumor types and chronic viral infections. Decoy previously held a pre-IND meeting with the FDA, currently plans to file an IND in the second half of 2021 and to initiate a Phase I clinical trial in 2022 targeting solid tumors and lymphomas.
Viracta Therapeutics Strengthens Company Leadership with New Appointments to the Board of Directors and Management Team
Stephen Rubino, Ph.D., MBA and Barry J. Simon, M.D. appointed to the Board of Directors
Cheryl A. Madsen, RAC appointed as Senior Vice President, Regulatory Affairs
News provided by
Share this article
Share this article
SAN DIEGO, March 4, 2021 /PRNewswire/ Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that it has strengthened its leadership team with the appointments of Drs. Stephen Rubino and Barry J. Simon to the Board of Directors, the addition of Cheryl A. Madsen, RAC as Senior Vice President, Regulatory Affairs, and the promotion of several members of the management team.